ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
CRSP US Financials Total Return

CRSP US Financials Total Return (CRSPFNT)

4,998.48
53.07
(1.07%)
Closed August 16 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
4,998.48
Price Change
53.07
Change %
1.07%
Name
CRSP US Financials Total Return
Symbol
CRSPFNT
4,945.53 Day's Range 5,016.34
0.00 52 Week Range 0.00
Bid
4,945.41
Ask
4,945.41
Open
4,945.53
High
5,016.34
Low
4,945.53
Close
4,998.48
Previous Close
4,945.41
Market
NASDAQ Indices
Type
Index

CRSPFNT Latest News

Sunesis Issued Important European Patent Covering Vosaroxin Clinical Formulation

SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that the European Patent Office (EPO) has granted European Patent No...

Sunesis to Present at ROTH 23rd Annual OC Growth Stock Conference

SOUTH SAN FRANCISCO, Calif., March 9, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...

Sunesis Pharmaceuticals Regains NASDAQ Compliance

SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that it has received notification from The NASDAQ Stock Market that it...

Sunesis to Present at Cowen and Company 31st Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 1, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD), a biopharmaceutical company focused on the development and commercialization of new...

Sunesis to Join Panel Discussion at the RBC Capital Markets' Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...

Sunesis Receives FDA Fast Track Designation for Vosaroxin in AML

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that vosaroxin, the Company's lead drug candidate, has been granted...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000IX
40000000IX
120000000IX
260000000IX
520000000IX
1560000000IX
2600000000IX
Indices
Commodities
Forex
US5005,530.700.000.00%
US3040,588.000.000.00%
US1002,674.000.000.00%
DJI40,563.06554.671.39%
SP5005,543.2288.011.61%
COMPX17,594.50401.902.34%
DXY102.5230.0230.02%

Your Recent History

Delayed Upgrade Clock